Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass
Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2
The Company also reminded those who have previously voted against Proxy Proposal #2 that they can change their vote in favor of the proposal if their ballots are cast by the deadline of
Proposal #2 is an amendment to the Company’s Restated Certificate of Incorporation to increase the authorized number of shares of its common stock to 250 million shares.
“Proposal #2 is important for shareholders and for the company, because it would enable us to continue to work to unlock and create value by investing in the business so that we can progress our programs,” said
“The vast majority of the shares voted, over 80%, are in favor of Proposal #2, including 8.3 million more shares in support of Proposal #2 since our Investor Q&A webcast on
A recording of the Investor Q&A webcast can be found here, and a transcript from the webcast can be found here.
Both leading independent proxy advisory firms,
Vaxart’s 2022 Annual Meeting of Stockholders was adjourned to
Stockholders of record on
Stockholders of
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "should," "believe," "could," "potential," "will," "expected," “anticipate,” "plan," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial data; and Vaxart's expectations with respect to the effectiveness of its product candidates. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's product candidates may not be approved by the FDA or non-
Contacts
Vaxart Media Relations: | Investor Relations: |
Mark Herr | |
mherr@vaxart.com |
IR@vaxart.com |
(203) 517-8957 | (646) 871-8486 |
Source: Vaxart, Inc.